Alamar Biosciences Launches NULISAseq Immune 340 Panel for Advanced Immune Profiling

Alamar Biosciences has launched the NULISAseq™ Immune 340 Panel, its broadest multiplexed immune profiling solution to date, designed to support translational research and drug development. The new panel builds on the company's NULISAseq Inflammation Panel 250 and enables researchers to measure approximately 340 immune-related proteins from a single sample.

The expanded panel is designed to provide deeper insights into the immune proteome by detecting key proteins that have previously been difficult or impossible to measure using conventional technologies. The solution could support research across a wide range of disease areas, including cancer, cardiovascular and metabolic diseases, autoimmune disorders, and aging.

“The immune system holds some of the earliest and most informative signals of disease, yet much of that biology has been out of reach,” said Dr. Yuling Luo, founder, chief executive officer and chair of Alamar. “NULISAseq Immune 340 gives researchers an unprecedented view of immune activity. We believe that this view will accelerate biomarker discovery, strengthen the development of new therapies and diagnostics, and advance our mission of detecting disease earlier and helping people stay healthier for longer.” 

Immune responses involve complex interactions between multiple proteins, biological pathways, and cell types rather than being driven by a single biomarker. By simultaneously analyzing a broad range of cytokines, chemokines, and other immune-related proteins, the Immune 340 Panel aims to give researchers greater context for understanding immune activation and identifying biological signals that may emerge before noticeable symptoms of disease.

“In drug development, the ability to simultaneously profile the full immune landscape – not just the well-characterized cytokines, but the entire network of checkpoints, metabolic regulators, cell death mediators, and co-stimulatory signals – fundamentally changes what we can learn from a single sample,” said Bailin Zhang, PhD, head of exploratory biomarkers in the Translational Medicine Unit at Sanofi. “What makes the NULISAseq Immune 340 Panel distinctive is the combination of breadth and sensitivity. Many of the proteins most relevant to immune mechanisms of action, resistance, and toxicity have historically been undetectable in blood. Having access to them, alongside the canonical markers, in one multiplexed run opens new possibilities for biomarker discovery and patient stratification.” 

The technology is particularly relevant to research into inflammaging, a form of persistent, low-level inflammation that develops with age and is associated with immune system aging and neuroimmune changes. These processes may contribute to the risk of cardiovascular, metabolic, neurodegenerative diseases and cancer. Many of the proteins involved in these pathways are present in extremely low concentrations, often at femtogram-per-milliliter or sub-picogram-per-milliliter levels, making them difficult to detect using traditional immunoassays. Alamar's new panel aims to make these previously hard-to-detect immune signals more accessible for research.